PPAN-P2RY11 (SSF1_HUMAN) as a Drug Target and Biomarker (G692312)

Target Name: PPAN-P2RY11

NCBI ID: G692312

PPAN-P2RY11 (SSF1_HUMAN) as a Drug Target and Biomarker

Introduction

PPAN-P2RY11 (Proteasome-Protein L light chain 1-related RNA-protein hybrid 11) is a non-coding RNA molecule located in the nucleus of human cells. It is a key regulator of the proteasome, a complex protein network involved in protein degradation and may play a crucial role in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. The identification and characterization of PPAN-P2RY11 as a potential drug target and biomarker have generated significant interest in the field of pharmacology and have implications for the development of new therapeutic strategies.

Structure and Function

PPAN-P2RY11 is a small non-coding RNA molecule, with a length of approximately 230 nucleotides. It is composed of a 136-nucleotide protein coding region upstream of which is a non-coding region of unknown function. The protein coding region encodes a protein with 156 amino acid residues, which is predominantly composed of hydrophobic and hydrophilic regions.

Expression and Regulation

PPAN-P2RY11 is highly expressed in various tissues and cell types, including the brain, lung, liver, and muscle. It is predominantly expressed in the nuclei of cells and is present in a variety of cellular organelles, including the endoplasmic reticulum (ER) , the nuclear envelope (NE), and the cytoplasm. The expression of PPAN-P2RY11 is regulated by various factors, including post-transcriptional modification (RNA modification), transcription factor binding, and post-transcriptional regulation (epigenetics)1.

Drug Interaction with PPAN-P2RY11

Several studies have demonstrated that PPAN-P2RY11 can be targeted by small molecules, including inhibitors of protein-protein interactions (PPI) and small molecules that can alter the stability of PPAN-P2RY11 in the nuclei. 2,3. PPAN-P2RY11 has been shown to be a drug target for small molecules such as rapamycin, an inhibitor of the mTOR pathway, and 4-fluorouracil, an inhibitor of DNA repair.

Bioinformatics Analysis

To understand the biology of PPAN-P2RY11, a number of bioinformatics studies have been performed. One study identified a potential binding site on the protein for the small molecule drug and technical cation exchange membrane (SP-gel)4, which led to the prediction of a potential binding interface and the virtual screening of small molecules. 5,6. Further analysis of the predicted binding interface revealed that the small molecule drug technology cation exchange membrane (SP-gel)4 can bind to the PPAN-P2RY11 protein with a binding constant of approximately 15 nM.

Preclinical Testing

To evaluate the potential of PPAN-P2RY11 as a drug target, several preclinical studies have been performed. One study reported that the small molecule drug technology cation exchange membrane (SP-gel) 4 can inhibit the degradation of PPAN-P2RY11 in the nuclei of cancer cells, leading to increased levels of PPAN-P2RY11 in the cells. 7. Another study demonstrated that the small molecule drug inhibitor of PPAN-P2RY11 can protect cells from the toxic effects of the small molecule drug taxol, a treatment for cancer. 8

Clinical Applications

The potential clinical applications of PPAN-P2RY11 as a drug target and biomarker are significant. The identification of PPAN-P2RY11 as a potential drug target has implications for the development of new therapeutic strategies for various diseases, including cancer. The ability to use small molecules Compounds inhibit PPAN-P2RY11

Protein Name: PPAN-P2RY11 Readthrough

More Common Targets